Glycerol phosphate serves as a terminator of glycan elongation in cancer malignancy

Stop for migration!
Increased expression of PCYT2, which synthesizes CDP-Gro in cancer, enhances GroP modification, and impairs matriglycan formation. This phenomenon allows cancer cells to leave the constraints of the extracellular matrix and gain migratory capacity. Credit: Nagoya City University Graduate School of Pharmaceutical Sciences

Dystroglycans on epithelial cell surfaces interact with the extracellular matrix via long sugar chains (called matriglycans), and they are responsible for cell adhesion. Abnormalities in the formation of matriglycans can impair cell adhesion and cause muscular dystrophy.

The collaborative groups, including researchers at Nagoya City University and National Institutes of Natural Sciences, have previously discovered the presence of a novel post-translational modification, in which glycerol phosphate (GroP) caps the core part of matriglycan, thereby blocking its elongation.

In this recent study published in the International Journal of Molecular Sciences, the researchers have shown that GroP modification is enhanced in . Moreover, this modification is promoted as cancer progresses. They established a human colon cancer cell line with increased GroP expression by overexpressing a bacterial enzyme that synthesizes CDP-Gro, a key precursor of GroP modification.

They have also demonstrated that these cells have an increased cell migration capacity. Furthermore, they have found a high correlation in colorectal cancer tissue between GroP modification and the expression of PCYT2, a CDP-Gro synthase in humans. These findings indicate that enhanced GroP modification in cancer cells can terminate matriglycan elongation, thereby disrupting , which in turn promotes the migration of cancer cells.

Their findings provide insights into : If enhanced GroP modification can promote malignant transformation of , then cancer metastasis can be inhibited by antagonizing this modification. Proteins involved in GroP modifications, such as PCYT2, are considered as potential targets for drug discovery. In addition, antibodies targeting GroP modification could be developed into antibody-based therapeutics against cancer.


Explore further

Researchers reveal discovery of mechanism leading to drug resistance in prostate cancer

More information: Fumiko Umezawa et al, Cancer Malignancy Is Correlated with Upregulation of PCYT2-Mediated Glycerol Phosphate Modification of α-Dystroglycan, International Journal of Molecular Sciences (2022). DOI: 10.3390/ijms23126662
Provided by Nagoya City University
Citation: Glycerol phosphate serves as a terminator of glycan elongation in cancer malignancy (2022, June 27) retrieved 18 August 2022 from https://phys.org/news/2022-06-glycerol-phosphate-terminator-glycan-elongation.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
6 shares

Feedback to editors